Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Evaluation of the Effect of Using Ultrasound Robots for Breast Cancer Screening

NCT07331363 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-12-10
Last updated
2026-10-29

Condition(s) studied

Breast CancerUltrasound

Investigational drug(s) / intervention(s)

Screening of the subjects was conducted using an ultrasonic robot.

Screening of the subjects was conducted using an ultrasonic robot.: The ultrasound robot automatically scans the breasts of subjects via its mechanical arm and generates images.The diagnosis is made based on the radiologist's interpretation of the images.

Study summary

The goal of this clinical trial is to learn if robotic ultrasound screening works as well as or better than traditional sonographer-led screening for detecting breast cancer. It will also explore how well participants follow recommended post-screening care. The main questions it aims to answer are:

Does robotic ultrasound screening detect more cases of breast cancer compared to traditional sonographer-led screening? How well do participants follow up on recommended care after robotic ultrasound screening? Researchers will compare robotic ultrasound screening to traditional sonographer-led screening to see if robotic ultrasound works effectively for breast cancer screening.

Participants will:

Receive a breast ultrasound performed either by a robotic system or a human sonographer.

Undergo follow-up management based on their BI-RADS classification.

Eligibility

Sex
FEMALE
Min age
35 Years
Max age
64 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. women aged 35-64 years 2. no history of breast cancer 3. ownership and ability to use a smartphone 4. willingness to participate in the screening program. Exclusion Criteria: 1. Women who have undergone breast removal surgery; 2. Pregnant and lactating women; 3. Women who have undergone breast cancer screening within the past year;

Primary outcome measure(s)

  • The detection rate of breast cancer — After participating in the screening, the subjects will be followed up for 24 months.
    Number of detected ductal carcinoma in situ (DCIS) and invasive breast cancers divided by the total number of screened participants.

Trial sites (1)

FacilityCityRegionStatus
Rural health centers and community health centers Xiantao Hubei Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07331363 on ClinicalTrials.gov ↗ ← All trials in China